Your browser doesn't support javascript.
loading
Induced Pluripotent Stem Cell-Based Modeling of Single-Ventricle Congenital Heart Diseases.
Parker, Lauren E; Kurzlechner, Leonie M; Landstrom, Andrew P.
Afiliação
  • Parker LE; Department of Pediatrics, Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
  • Kurzlechner LM; Department of Pediatrics, Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
  • Landstrom AP; Department of Pediatrics, Division of Cardiology, Duke University School of Medicine, Durham, NC, USA. andrew.landstrom@duke.edu.
Curr Cardiol Rep ; 25(5): 295-305, 2023 05.
Article em En | MEDLINE | ID: mdl-36930454
ABSTRACT
PURPOSE OF REVIEW Congenital heart disease includes a wide variety of structural cardiac defects, the most severe of which are single ventricle defects (SVD). These patients suffer from significant morbidity and mortality; however, our understanding of the developmental etiology of these conditions is limited. Model organisms offer a window into normal and abnormal cardiogenesis yet often fail to recapitulate complex congenital heart defects seen in patients. The use of induced pluripotent stem cells (iPSCs) derived from patients with single-ventricle defects opens the door to studying SVD in patient-derived cardiomyocytes (iPSC-CMs) in a variety of different contexts, including organoids and chamber-specific cardiomyocytes. As the genetic and cellular causes of SVD are not well defined, patient-derived iPSC-CMs hold promise for uncovering mechanisms of disease development and serve as a platform for testing therapies. The purpose of this review is to highlight recent advances in iPSC-based models of SVD. RECENT

FINDINGS:

Recent advances in patient-derived iPSC-CM differentiation, as well as the development of both chamber-specific and non-myocyte cardiac cell types, make it possible to model the complex genetic and molecular architecture involved in SVD development. Moreover, iPSC models have become increasingly complex with the generation of 3D organoids and engineered cardiac tissues which open the door to new mechanistic insight into SVD development. Finally, iPSC-CMs have been used in proof-of-concept studies that the molecular underpinnings of SVD may be targetable for future therapies. While each platform has its advantages and disadvantages, the use of patient-derived iPSC-CMs offers a window into patient-specific cardiogenesis and SVD development. Advancement in stem-cell based modeling of SVD promises to revolutionize our understanding of the developmental etiology of SVD and provides a tool for developing and testing new therapies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células-Tronco Pluripotentes Induzidas / Cardiopatias Congênitas Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células-Tronco Pluripotentes Induzidas / Cardiopatias Congênitas Idioma: En Ano de publicação: 2023 Tipo de documento: Article